KR102457848B1 - Mk2 억제제 및 이의 용도 - Google Patents

Mk2 억제제 및 이의 용도 Download PDF

Info

Publication number
KR102457848B1
KR102457848B1 KR1020177010439A KR20177010439A KR102457848B1 KR 102457848 B1 KR102457848 B1 KR 102457848B1 KR 1020177010439 A KR1020177010439 A KR 1020177010439A KR 20177010439 A KR20177010439 A KR 20177010439A KR 102457848 B1 KR102457848 B1 KR 102457848B1
Authority
KR
South Korea
Prior art keywords
compound
disorder
disease
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010439A
Other languages
English (en)
Korean (ko)
Other versions
KR20170063734A (ko
Inventor
매튜 데이비드 알렉산더
클라우디오 촤쿠이
존 말로나
조셉 존 맥도날드
야이크 니
더창 뉴
러셀 씨. 피터
저스윈더 싱
치타리 파바
묘 궈빈
Original Assignee
셀젠 카르 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀젠 카르 엘엘씨 filed Critical 셀젠 카르 엘엘씨
Publication of KR20170063734A publication Critical patent/KR20170063734A/ko
Application granted granted Critical
Publication of KR102457848B1 publication Critical patent/KR102457848B1/ko
Assigned to 브리스톨-마이어스 스큅 컴퍼니 reassignment 브리스톨-마이어스 스큅 컴퍼니 권리의 전부이전등록 Assignors: 셀젠 카르 엘엘씨
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020177010439A 2014-09-17 2015-09-16 Mk2 억제제 및 이의 용도 Active KR102457848B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
KR20170063734A KR20170063734A (ko) 2017-06-08
KR102457848B1 true KR102457848B1 (ko) 2022-10-25

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010439A Active KR102457848B1 (ko) 2014-09-17 2015-09-16 Mk2 억제제 및 이의 용도

Country Status (30)

Country Link
US (5) US9458175B2 (enExample)
EP (2) EP3912981A1 (enExample)
JP (3) JP6556225B2 (enExample)
KR (1) KR102457848B1 (enExample)
CN (1) CN106998692B (enExample)
AU (1) AU2015317741B2 (enExample)
BR (1) BR112017005266B1 (enExample)
CA (1) CA2961607C (enExample)
CL (1) CL2017000576A1 (enExample)
CO (1) CO2017003279A2 (enExample)
CY (1) CY1124215T1 (enExample)
DK (1) DK3193611T3 (enExample)
EA (1) EA037299B1 (enExample)
EC (1) ECSP17023281A (enExample)
ES (1) ES2874561T3 (enExample)
HR (1) HRP20210529T1 (enExample)
HU (1) HUE054347T2 (enExample)
IL (1) IL251051B (enExample)
LT (1) LT3193611T (enExample)
MA (1) MA40534B1 (enExample)
MX (2) MX373341B (enExample)
PL (1) PL3193611T3 (enExample)
PT (1) PT3193611T (enExample)
RS (1) RS62017B1 (enExample)
SA (1) SA517381115B1 (enExample)
SG (2) SG11201701861RA (enExample)
SI (1) SI3193611T1 (enExample)
SM (1) SMT202100311T1 (enExample)
TW (1) TWI744217B (enExample)
WO (1) WO2016044463A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596086A4 (en) * 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP7692353B2 (ja) * 2018-10-02 2025-06-13 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
US12594277B2 (en) 2020-02-14 2026-04-07 Salk Institute For Biological Studies Macrocyclic ULK1/2 inhibitors
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
WO2022020562A1 (en) * 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CA3201774A1 (en) * 2020-11-12 2022-05-19 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
US12668598B2 (en) 2022-10-27 2026-06-30 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
KR20250139398A (ko) * 2023-02-07 2025-09-23 셀진 코포레이션 Mk2 키나제의 분해제로서 유용한 화합물 및 조성물
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137708A1 (en) 2010-06-04 2013-05-30 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20140018343A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN112029513B (zh) 2012-02-22 2024-02-23 默克专利股份有限公司 液晶介质
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
CN104981791A (zh) * 2012-09-24 2015-10-14 克莱尔蒙特·斯皮德 移动发送方控制的数据访问和数据删除方法和系统
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
US10138256B2 (en) * 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137708A1 (en) 2010-06-04 2013-05-30 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20140018343A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 2009, Vol.19, pp.4882-4884.
Journal of Medicinal Chemistry, 2012, Vol.55, pp.2035-2047.

Also Published As

Publication number Publication date
WO2016044463A3 (en) 2016-09-01
WO2016044463A2 (en) 2016-03-24
AU2015317741A1 (en) 2017-04-20
IL251051A0 (en) 2017-04-30
AU2015317741B2 (en) 2020-01-16
SA517381115B1 (ar) 2021-03-09
IL251051B (en) 2019-11-28
MA40534B1 (fr) 2021-04-30
SI3193611T1 (sl) 2021-08-31
JP2022078315A (ja) 2022-05-24
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
JP7375072B2 (ja) 2023-11-07
MA40534A (fr) 2016-03-24
US11584757B2 (en) 2023-02-21
BR112017005266B1 (pt) 2022-11-01
EP3193611A4 (en) 2018-02-28
EA037299B1 (ru) 2021-03-05
CO2017003279A2 (es) 2017-09-29
TWI744217B (zh) 2021-11-01
EA201790380A1 (ru) 2017-08-31
US9458175B2 (en) 2016-10-04
HUE054347T2 (hu) 2021-08-30
JP2019194236A (ja) 2019-11-07
TW201617351A (zh) 2016-05-16
KR20170063734A (ko) 2017-06-08
US20170114073A1 (en) 2017-04-27
EP3193611A2 (en) 2017-07-26
EP3912981A1 (en) 2021-11-24
NZ730603A (en) 2024-02-23
CA2961607A1 (en) 2016-03-24
CN106998692B (zh) 2020-09-08
LT3193611T (lt) 2021-08-25
US20210053984A1 (en) 2021-02-25
CN106998692A (zh) 2017-08-01
SMT202100311T1 (it) 2021-07-12
MX2017003359A (es) 2017-11-22
SG11201701861RA (en) 2017-04-27
US9790235B2 (en) 2017-10-17
MX373341B (es) 2020-05-26
DK3193611T3 (da) 2021-05-10
MX2020005213A (es) 2020-08-20
EP3193611B1 (en) 2021-03-24
PT3193611T (pt) 2021-05-28
JP6556225B2 (ja) 2019-08-07
US10577380B2 (en) 2020-03-03
CA2961607C (en) 2023-03-28
PL3193611T3 (pl) 2021-10-04
US10253040B1 (en) 2019-04-09
CL2017000576A1 (es) 2017-12-01
US20160075720A1 (en) 2016-03-17
ECSP17023281A (es) 2017-06-30
JP2017529367A (ja) 2017-10-05
SG10201902326XA (en) 2019-04-29
RS62017B1 (sr) 2021-07-30
CY1124215T1 (el) 2022-05-27
US20190375762A1 (en) 2019-12-12
BR112017005266A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
JP7375072B2 (ja) Ｍｋ２阻害剤およびその使用
TWI675833B (zh) 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑
KR20230170658A (ko) 유비퀴틴 특이적 프로테아제 1(usp1) 억제제
US11098057B2 (en) 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
JP2019081786A (ja) Ｔｒｋａキナーゼ阻害剤としてのｎ−ピロリジニル、ｎ’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
US20180222893A1 (en) Heteroaromatic compounds as btk inhibitors
CN107344940A (zh) Btk抑制剂及其用途
WO2024092115A2 (en) Mk2 inhibitors and uses thereof
HK1241225B (en) Mk2 inhibitors and uses thereof
HK1241225A1 (en) Mk2 inhibitors and uses thereof
CN117940433A (zh) 喹啉并呋喃衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200914

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220802

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221019

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221020

End annual number: 3

Start annual number: 1

PG1601 Publication of registration